XBI State Street SPDR S&P Biotech ETF
168.21
-0.18 (-0.11%)
报价截至 Aug 27, 2026 14:38 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
关于本ETF
SPDR Series Trust - State Street SPDR S&P Biotech ETF is an exchange traded fund launched by State Street Global Advisors, Inc. The fund is managed by SSGA Funds Management, Inc. It invests in public equity markets of the United States. It invests in stocks of companies operating across health care, pharmaceuticals, biotechnology and life sciences sectors. The fund invests in growth and value stocks of companies across diversified market capitalization. It seeks to track the performance of the S&P Biotechnology Select Industry Index, by using representative sampling technique. SPDR Series Trust - State Street SPDR S&P Biotech ETF was formed on January 31, 2006 and is domiciled in the United States.
来自基金数据提供商的描述 · 截至以下日期的概况： Aug 27, 2026.
价格走势图
每日收盘价（价格回报，非总回报）。对比折线图以区间起始点为基准，标准化为百分比变动。 来源: Financial Modeling Prep.
业绩表现
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | 成立* | |
|---|---|---|---|---|---|---|---|---|---|
| 价格回报 | +11.82% | +25.24% | +31.27% | +38.10% | +87.31% | +28.83% | +4.99% | +10.67% | +11.99% |
| 总回报 | +11.82% | +25.36% | +31.40% | +38.24% | +88.17% | +29.10% | +5.12% | +10.83% | +12.31% |
* 已年化。总回报率采用股息调整后价格序列计算（分红再投入）；价格回报率采用未经调整的收盘价计算。 业绩截至 Aug 26, 2026. 过往业绩不代表未来表现。
费率
| 净费率 | 0.35% | 每10,000美元投资的年化费用 | $35.00 |
仅供示意的费用测算：费用率 × $10,000。不含交易成本、买卖价差、税费及投资价值变动。总费用率与净费用率的详情及任何费用减免安排，请参阅招募说明书。
持仓明细
持仓数据截至 Aug 26, 2026 — 数据提供商报告的投资组合日期；持仓数据非实时仓位。 157 数据库总行数.
| # | 持仓 | 代码 | 权重 | 股票 | 市值 |
|---|---|---|---|---|---|
| 1 | MODERNA INC | MRNA | 3.05% | 2.33M | $342.8M |
| 2 | TWIST BIOSCIENCE CORP | TWST | 1.98% | 1.58M | $221.8M |
| 3 | APOGEE THERAPEUTICS INC | APGE | 1.44% | 1.30M | $161.8M |
| 4 | KYMERA THERAPEUTICS INC | KYMR | 1.43% | 1.37M | $160.7M |
| 5 | ORUKA THERAPEUTICS INC | ORKA | 1.41% | 1.68M | $157.8M |
| 6 | NATERA INC | NTRA | 1.38% | 495.55K | $154.4M |
| 7 | HALOZYME THERAPEUTICS INC | HALO | 1.37% | 1.52M | $153.9M |
| 8 | PRAXIS PRECISION MEDICINES I | PRAX | 1.35% | 445.69K | $151.8M |
| 9 | DIANTHUS THERAPEUTICS INC | DNTH | 1.30% | 1.40M | $145.6M |
| 10 | REVOLUTION MEDICINES INC | RVMD | 1.30% | 743.94K | $145.5M |
| 11 | CG ONCOLOGY INC | CGON | 1.27% | 1.95M | $142.7M |
| 12 | TRAVERE THERAPEUTICS INC | TVTX | 1.27% | 2.30M | $142.3M |
| 13 | SPYRE THERAPEUTICS INC | SYRE | 1.26% | 1.43M | $141.9M |
| 14 | PROTAGONIST THERAPEUTICS INC | PTGX | 1.26% | 1.01M | $141.3M |
| 15 | REGENERON PHARMACEUTICALS | REGN | 1.22% | 178.27K | $137.5M |
| 16 | INSMED INC | INSM | 1.19% | 1.17M | $133.8M |
| 17 | VAXCYTE INC | PCVX | 1.19% | 2.36M | $133.5M |
| 18 | ERASCA INC | ERAS | 1.17% | 8.02M | $131.9M |
| 19 | RHYTHM PHARMACEUTICALS INC | RYTM | 1.17% | 1.25M | $131.3M |
| 20 | SCHOLAR ROCK HOLDING CORP | SRRK | 1.17% | 2.43M | $131.1M |
| 21 | AMGEN INC | AMGN | 1.16% | 317.72K | $130.0M |
| 22 | RELAY THERAPEUTICS INC | RLAY | 1.15% | 6.79M | $129.3M |
| 23 | ROIVANT SCIENCES LTD | ROIV | 1.13% | 3.78M | $127.4M |
| 24 | VERTEX PHARMACEUTICALS INC | VRTX | 1.12% | 246.07K | $125.9M |
| 25 | ARROWHEAD PHARMACEUTICALS IN | ARWR | 1.11% | 1.52M | $124.7M |
| 26 | CRISPR THERAPEUTICS AG | CRSP | 1.09% | 2.17M | $122.3M |
| 27 | VIKING THERAPEUTICS INC | VKTX | 1.09% | 3.87M | $122.2M |
| 28 | INCYTE CORP | INCY | 1.09% | 1.02M | $122.2M |
| 29 | IOVANCE BIOTHERAPEUTICS INC | IOVA | 1.09% | 15.65M | $122.2M |
| 30 | UNIQURE NV | QURE | 1.09% | 2.58M | $122.0M |
| 31 | SELLAS LIFE SCIENCES GROUP I | SLS | 1.08% | 9.32M | $121.6M |
| 32 | GILEAD SCIENCES INC | GILD | 1.08% | 882.48K | $121.5M |
| 33 | ACADIA PHARMACEUTICALS INC | ACAD | 1.08% | 4.29M | $121.2M |
| 34 | BRIDGEBIO PHARMA INC | BBIO | 1.05% | 1.59M | $118.4M |
| 35 | TG THERAPEUTICS INC | TGTX | 1.05% | 2.30M | $118.0M |
| 36 | GRAIL INC | GRAL | 1.04% | 1.54M | $117.3M |
| 37 | ABBVIE INC | ABBV | 1.04% | 476.53K | $117.2M |
| 38 | BIOMARIN PHARMACEUTICAL INC | BMRN | 1.04% | 1.91M | $116.9M |
| 39 | COGENT BIOSCIENCES INC | COGT | 1.04% | 3.42M | $116.4M |
| 40 | CYTOKINETICS INC | CYTK | 1.02% | 1.60M | $114.7M |
| 41 | KRYSTAL BIOTECH INC | KRYS | 1.01% | 343.48K | $113.2M |
| 42 | BIOGEN INC | BIIB | 1.00% | 552.40K | $112.8M |
| 43 | IMMUNOVANT INC | IMVT | 1.00% | 2.78M | $111.7M |
| 44 | ALKERMES PLC | ALKS | 0.99% | 2.45M | $111.4M |
| 45 | DYNE THERAPEUTICS INC | DYN | 0.97% | 4.47M | $109.0M |
| 46 | MADRIGAL PHARMACEUTICALS INC | MDGL | 0.96% | 227.38K | $107.8M |
| 47 | EXELIXIS INC | EXEL | 0.95% | 2.04M | $107.0M |
| 48 | BEAM THERAPEUTICS INC | BEAM | 0.93% | 3.64M | $104.4M |
| 49 | CELCUITY INC | CELC | 0.92% | 1.21M | $103.7M |
| 50 | MIRUM PHARMACEUTICALS INC | MIRM | 0.92% | 1.14M | $103.6M |
| 51 | IMMUNITYBIO INC | IBRX | 0.91% | 13.45M | $101.9M |
| 52 | PTC THERAPEUTICS INC | PTCT | 0.88% | 1.46M | $99.3M |
| 53 | SUMMIT THERAPEUTICS INC | SMMT | 0.88% | 8.03M | $99.3M |
| 54 | IDEAYA BIOSCIENCES INC | IDYA | 0.87% | 2.49M | $98.0M |
| 55 | ULTRAGENYX PHARMACEUTICAL IN | RARE | 0.86% | 3.95M | $96.7M |
| 56 | NEUROCRINE BIOSCIENCES INC | NBIX | 0.84% | 666.46K | $94.6M |
| 57 | UNITED THERAPEUTICS CORP | UTHR | 0.84% | 197.08K | $94.6M |
| 58 | VIRIDIAN THERAPEUTICS INC | VRDN | 0.84% | 4.22M | $94.5M |
| 59 | BIOCRYST PHARMACEUTICALS INC | BCRX | 0.84% | 10.31M | $93.8M |
| 60 | VERA THERAPEUTICS INC | VERA | 0.83% | 2.85M | $93.1M |
| 61 | IMMUNOME INC | IMNM | 0.78% | 3.23M | $87.8M |
| 62 | DENALI THERAPEUTICS INC | DNLI | 0.77% | 3.74M | $86.3M |
| 63 | IONIS PHARMACEUTICALS INC | IONS | 0.77% | 1.46M | $86.0M |
| 64 | SAREPTA THERAPEUTICS INC | SRPT | 0.75% | 4.80M | $84.1M |
| 65 | CELLDEX THERAPEUTICS INC | CLDX | 0.74% | 2.18M | $83.2M |
| 66 | ALNYLAM PHARMACEUTICALS INC | ALNY | 0.73% | 368.03K | $81.8M |
| 67 | ARCUS BIOSCIENCES INC | RCUS | 0.72% | 2.79M | $81.4M |
| 68 | DISC MEDICINE INC | IRON | 0.70% | 1.03M | $78.7M |
| 69 | RECURSION PHARMACEUTICALS A | RXRX | 0.70% | 23.83M | $78.5M |
| 70 | INTELLIA THERAPEUTICS INC | NTLA | 0.69% | 6.20M | $77.5M |
| 71 | ADMA BIOLOGICS INC | ADMA | 0.67% | 8.39M | $75.4M |
| 72 | HYPERLIQUID STRATEGIES | PURR | 0.67% | 6.83M | $75.0M |
| 73 | MINERALYS THERAPEUTICS INC | MLYS | 0.66% | 3.04M | $74.0M |
| 74 | ARCUTIS BIOTHERAPEUTICS INC | ARQT | 0.64% | 3.14M | $72.2M |
| 75 | TANGO THERAPEUTICS INC | TNGX | 0.64% | 3.11M | $71.3M |
| 76 | NOVAVAX INC | NVAX | 0.63% | 8.10M | $70.8M |
| 77 | SYNDAX PHARMACEUTICALS INC | SNDX | 0.62% | 3.80M | $70.0M |
| 78 | AGIOS PHARMACEUTICALS INC | AGIO | 0.60% | 2.16M | $67.7M |
| 79 | NURIX THERAPEUTICS INC | NRIX | 0.59% | 2.65M | $66.2M |
| 80 | VERACYTE INC | VCYT | 0.58% | 1.61M | $65.6M |
| 81 | PALVELLA THERAPEUTICS INC | PVLA | 0.54% | 441.23K | $60.5M |
| 82 | KODIAK SCIENCES INC | KOD | 0.52% | 1.61M | $58.9M |
| 83 | CAREDX INC | CDNA | 0.52% | 1.23M | $58.0M |
| 84 | XENCOR INC | XNCR | 0.51% | 2.09M | $56.8M |
| 85 | CULLINAN THERAPEUTICS INC | CGEM | 0.49% | 2.57M | $54.5M |
| 86 | BIOHAVEN LTD | BHVN | 0.48% | 4.09M | $54.4M |
| 87 | VIR BIOTECHNOLOGY INC | VIR | 0.47% | 5.34M | $52.9M |
| 88 | STOKE THERAPEUTICS INC | STOK | 0.47% | 1.70M | $52.6M |
| 89 | VERICEL CORP | VCEL | 0.46% | 1.29M | $51.6M |
| 90 | PRECIGEN INC | PGEN | 0.46% | 7.65M | $51.5M |
| 91 | ABSCI CORP | ABSI | 0.44% | 5.58M | $49.7M |
| 92 | INHIBRX BIOSCIENCES INC | INBX | 0.44% | 432.91K | $49.2M |
| 93 | ANAPTYSBIO INC | ANAB | 0.41% | 848.95K | $45.9M |
| 94 | ZENAS BIOPHARMA INC | ZBIO | 0.41% | 1.46M | $45.5M |
| 95 | ORIC PHARMACEUTICALS INC | ORIC | 0.40% | 3.52M | $45.1M |
| 96 | REPLIMUNE GROUP INC | REPL | 0.39% | 2.96M | $43.3M |
| 97 | CORVUS PHARMACEUTICALS INC | CRVS | 0.38% | 3.16M | $42.6M |
| 98 | VOR BIOPHARMA INC | VOR | 0.38% | 1.90M | $42.1M |
| 99 | FIRST TRACKS BIOTHERAPEUTICS | TRAX | 0.37% | 1.00M | $41.9M |
| 100 | KURA ONCOLOGY INC | KURA | 0.37% | 3.32M | $41.7M |
| 101 | AVALO THERAPEUTICS INC | AVTX | 0.36% | 2.19M | $40.0M |
| 102 | TYRA BIOSCIENCES INC | TYRA | 0.33% | 1.50M | $37.1M |
| 103 | JANUX THERAPEUTICS INC | JANX | 0.32% | 2.08M | $36.0M |
| 104 | MANNKIND CORP | MNKD | 0.32% | 9.19M | $35.4M |
| 105 | TAYSHA GENE THERAPIES INC | TSHA | 0.31% | 6.01M | $34.5M |
| 106 | GERON CORP | GERN | 0.30% | 23.55M | $33.8M |
| 107 | JADE BIOSCIENCES INC | JBIO | 0.30% | 1.66M | $33.5M |
| 108 | ANNEXON INC | ANNX | 0.29% | 6.73M | $32.1M |
| 109 | MONTE ROSA THERAPEUTICS INC | GLUE | 0.27% | 2.28M | $30.7M |
| 110 | IMMIX BIOPHARMA INC | IMMX | 0.27% | 2.27M | $30.4M |
| 111 | RIGEL PHARMACEUTICALS INC | RIGL | 0.27% | 701.90K | $30.4M |
| 112 | OLEMA PHARMACEUTICALS INC | OLMA | 0.26% | 2.93M | $29.6M |
| 113 | SANA BIOTECHNOLOGY INC | SANA | 0.26% | 7.64M | $29.0M |
| 114 | ARDELYX INC | ARDX | 0.25% | 8.01M | $28.0M |
| 115 | CANDEL THERAPEUTICS INC | CADL | 0.24% | 2.18M | $27.5M |
| 116 | ARRIVENT BIOPHARMA INC | AVBP | 0.24% | 946.76K | $27.5M |
| 117 | BICARA THERAPEUTICS INC | BCAX | 0.24% | 1.18M | $26.9M |
| 118 | CYTOMX THERAPEUTICS INC | CTMX | 0.24% | 8.60M | $26.8M |
| 119 | ALLOGENE THERAPEUTICS INC | ALLO | 0.23% | 13.11M | $26.3M |
| 120 | ALTIMMUNE INC | ALT | 0.23% | 8.74M | $25.9M |
| 121 | SOLID BIOSCIENCES INC | SLDB | 0.23% | 2.79M | $25.5M |
| 122 | 4D MOLECULAR THERAPEUTICS IN | FDMT | 0.22% | 1.74M | $25.3M |
| 123 | IRONWOOD PHARMACEUTICALS INC | IRWD | 0.21% | 5.94M | $24.1M |
| 124 | VERASTEM INC | VSTM | 0.21% | 3.66M | $24.0M |
| 125 | DAMORA THERAPEUTICS INC | DMRA | 0.19% | 771.64K | $21.9M |
| 126 | OCUGEN INC | OCGN | 0.17% | 15.10M | $19.6M |
| 127 | PRIME MEDICINE INC | PRME | 0.17% | 5.64M | $19.4M |
| 128 | ARBUTUS BIOPHARMA CORP | ABUS | 0.17% | 3.97M | $19.1M |
| 129 | CAPRICOR THERAPEUTICS INC | CAPR | 0.16% | 2.34M | $18.0M |
| 130 | SAVARA INC | SVRA | 0.16% | 3.45M | $17.9M |
| 131 | REGENXBIO INC | RGNX | 0.16% | 2.11M | $17.4M |
| 132 | COMPASS THERAPEUTICS INC | CMPX | 0.15% | 7.38M | $17.3M |
| 133 | CABALETTA BIO INC | CABA | 0.15% | 5.67M | $16.9M |
| 134 | OVID THERAPEUTICS INC | OVID | 0.13% | 5.31M | $14.3M |
| 135 | PROTHENA CORP PLC | PRTA | 0.12% | 1.57M | $13.7M |
| 136 | PERSPECTIVE THERAPEUTICS INC | CATX | 0.12% | 4.36M | $13.3M |
| 137 | ARS PHARMACEUTICALS INC | SPRY | 0.12% | 2.47M | $13.1M |
| 138 | MIMEDX GROUP INC | MDXG | 0.11% | 3.19M | $12.8M |
| 139 | VANDA PHARMACEUTICALS INC | VNDA | 0.11% | 2.47M | $12.5M |
| 140 | LEXEO THERAPEUTICS INC | LXEO | 0.11% | 2.62M | $12.4M |
| 141 | ACHIEVE LIFE SCIENCES INC | ACHV | 0.10% | 1.46M | $11.0M |
| 142 | SAGIMET BIOSCIENCES INC A | SGMT | 0.09% | 1.06M | $10.1M |
| 143 | EMERGENT BIOSOLUTIONS INC | EBS | 0.09% | 1.84M | $9.6M |
| 144 | MYRIAD GENETICS INC | MYGN | 0.09% | 3.26M | $9.6M |
| 145 | BRIDGEBIO ONCOLOGY THERAPEUT | BBOT | 0.07% | 877.78K | $7.6M |
| 146 | CONTRA METSERA INC | — | 0.06% | 1.53M | $6.9M |
| 147 | MAPLIGHT THERAPEUTICS INC | MPLT | 0.06% | 538.09K | $6.2M |
| 148 | SIONNA THERAPEUTICS INC | SION | 0.04% | 699.09K | $4.0M |
| 149 | SSI US GOV MONEY MARKET CLASS | — | 0.02% | 2.00M | $1.8M |
| 150 | CONTRA AKERO THERAPEUT | — | 0.01% | 2.03M | $1.2M |
| 151 | CONTRA INHIBRX INC | — | 0.01% | 1.65M | $989.9K |
| 152 | CONTRA MIRATI THERAPEU | — | 0.01% | 1.37M | $887.1K |
| 153 | CONTRA VERVE THERAPEUT | — | 0.00% | 900.27K | $524.8K |
| 154 | CONTRA BLUEPRINT MEDIC | — | 0.00% | 756.47K | $322.0K |
| 155 | US DOLLAR | — | 0.00% | 6.00K | $5.5K |
| 156 | OMNIAB INC 15.00 EARNOUT | 2200964D | 0.00% | 161.96K | $0.00 |
| 157 | OMNIAB INC 12.5 EARNOUT | 2200963D | 0.00% | 161.96K | $0.00 |
点击股票代码，查看所有持有该证券的ETF。
行业敞口
地区敞口
国家/地区权重以数据提供商报告为准。发达/新兴/前沿市场的分类标签遵循方法论页面中的分类标准。 货币对冲: 基金名称中未显示对冲信息.
分红记录
| 收益率（TTM） | 0.34% | 已派发（过去12个月） | $0.5713 |
| 频率 | Semi-Annual | SEC收益率 | 我们的数据来源未提供此信息——请参阅发行方页面 |
| 最近除息日 | Jun 22, 2026 | 最近派息 | $0.1381 (Jun 24, 2026) |
| 1年增长率 | +1775.58% | 3年/5年增长率（年化） | +501.89% / +13.37% |
| 除息日 | 股权登记日 | 派息日 | 金额 |
|---|---|---|---|
| Jun 22, 2026 | Jun 22, 2026 | Jun 24, 2026 | $0.1381 |
| Dec 22, 2025 | Dec 22, 2025 | Dec 24, 2025 | $0.4066 |
| Sep 22, 2025 | Sep 22, 2025 | Sep 24, 2025 | $0.0267 |
| Jun 23, 2025 | Jun 23, 2025 | Jun 25, 2025 | $0.0073 |
| Mar 24, 2025 | Mar 24, 2025 | Mar 26, 2025 | $0.0053 |
| Dec 23, 2024 | Dec 23, 2024 | Dec 26, 2024 | $0.0027 |
| Sep 23, 2024 | Sep 23, 2024 | Sep 25, 2024 | $0.0152 |
| Jun 24, 2024 | Jun 24, 2024 | Jun 26, 2024 | $0.1148 |
| Dec 18, 2023 | Dec 19, 2023 | Dec 21, 2023 | $0.0139 |
| Jun 20, 2023 | Jun 21, 2023 | Jun 23, 2023 | $0.0026 |
| Mar 22, 2021 | Mar 23, 2021 | Mar 25, 2021 | $0.0400 |
| Dec 21, 2020 | Dec 22, 2020 | Dec 24, 2020 | $0.1760 |
追踪分派收益率 = 过去 12 个月现金分派 ÷ 当前价格。此数据并非 SEC 30 日收益率，且分派金额不保证持续。 差异解析 →
风险统计
| 波动率 1年 / 3年 | 27.86% / 27.92% | 夏普比率（1年）/（3年） | 3.31 / 1.10 |
| 最大回撤 1年 / 3年 | -10.51% / -33.00% | 索提诺比率（1年） | 5.47 |
| 相对标普500的Beta值（近3年） | 1.00 | 与标普500的相关性（1年） | 0.445 |
| 下行偏差 1年 | 16.88% | 所用无风险利率 | 3.71% (3M T-bill, FRED) |
计算方式： ETF Explorer 基于每日股息调整后收盘价；波动率与最大回撤已年化/按区间计算；标普500敞口以SPY作为代理指标。 截至 Aug 27, 2026. 计算公式 →
流动性
| 今日成交量 | 1.26M | 平均成交量 | 8.75M |
| AUM | $11.92B | 溢价/折价 | -0.54% |
| 买卖价差 | 我们的数据来源未提供此信息。请查看您券商的报价页面；买卖价差在开盘和收盘时最大。 | ||
溢价/折价将延迟市场价格与最近披露的净值（NAV）进行比较——此数据为参考性数据，并非官方收盘溢价/折价。 ETF流动性机制详解 →
资金流量（估算）
| 期间 | 预估净流量 | 占初始AUM的% | AUM期初→期末 |
|---|---|---|---|
| 1日 | $695.1M | +6.19% | $11.23B → $11.92B |
| 1周 | $774.9M | +7.16% | $10.82B → $11.92B |
ETF Explorer估算：报告AUM变动减去市场涨跌影响，来源于我们自有的每日快照。非官方发行商申购/赎回数据。
基金官方资源
外部链接将在新标签页中打开发行商官网或SEC EDGAR。招募说明书及官方文件始终是权威依据——投资前请务必仔细阅读。
最新资讯： XBI
过去7天内暂无文章直接提及该基金——显示ETF行业综合报道。
Some Top-Tier Dividend Ideas Reside in SDOG ↗
One or two solid dividend stocks can do a portfolio well, but a broad basket of such names accessible in efficient fashion is an enticing proposition…
ETF Trends · Aug 27, 12:30 UTC
Is It Time to Cozy up to KORU Again? ↗
There’s no shortage of stocks that provide risk-tolerant traders with excitement. Plenty of ETFs accomplish that objective, too. But there are…
ETF Trends · Aug 27, 12:15 UTC
Tackle Inflation & Uncertainty With an Insider + Value Approach ↗
So far, 2026 has been a year full of macroeconomic events and market drivers, but one thing that has been consistent — for lack of a better term — is…
ETF Trends · Aug 27, 12:00 UTC
The Diary of Different Yields ↗
SUMMARY Earnings and dividend yields are important metrics for evaluating stocks. SEC yields net dividend and interest income against fund fees, in…
ETF Trends · Aug 27, 10:17 UTC
Blast Resources Appoints Andy Yackulic as an Independent Director ↗
Vancouver, British Columbia--(Newsfile Corp. - August 27, 2026) - Blast Resources Inc. (CSE: BLST) (FSE: O0E) (OTCQB: BLSRF) ("Blast" or the…
Newsfile Corp · Aug 27, 09:30 UTC
Gold Price Faces $4,700 Resistance With $4,500 Support in Focus ↗
Gold price struggles at $4,700 resistance ahead of key Fed signals, with $4,500 offering support while a break above $4,800 could revive momentum.
FXEmpire · Aug 27, 09:24 UTC
全部相关资讯： XBI →
使用指引：AUM为基金规模；费用率为内嵌于收益中的年度成本；NAV为基金每份资产净值，市场价格可能略高于NAV（溢价）或略低于NAV（折价）；总回报假设分配收益已再投资。每项数据集均显示各自的截止日期，因为持仓、资产和报价的更新频率不同。